BoomRay Pharmaceuticals Co., Ltd. is a clinical-stage biotech focusing on delivering innovative radionuclide Drug Conjugates (RDC) for precise tumor diagnosis and treatment. Currently, BoomRay has multiple clinical-stage products. In 2022, BoomRay completed nearly RMB300 million in Series A financing. At present, BoomRay has a number of proprietary diagnostic and therapeutic radionuclide drugs under research, with independent intellectual property rights. Headquartered in Suzhou, BoomRay has also established business departments for new drug discovery, clinical translations, and registration in Beijing and Shanghai. The company has a management team led by overseas high-profile talents with rich backgrounds in the nuclear medicine industry and experience in drug design and translation. Relying on the technology platforms and basic research infrastructures of Peking University, and cooperating with many hospitals, BoomRay is committed to building itself into a first-class nuclear medicine company with original innovation and highly efficient industrial translation capabilities.
Our Vision: Becoming a world-class innovation technology development and translational platform for radiopharmaceuticals
Our Mission: delivering innovative radiopharmaceuticals to patients around the world
